Loading data for ARQT — first visit, this takes a few seconds.

Arcutis Biotherapeutics, Inc. (ARQT)

NasdaqGS: ARQT · Real-Time Price · USD

24.87

-0.27 (-1.07%)

At close: Aug 28, 2026, 8:00 PM

23.74

-0.17%

After-hours: 7:30 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	17.93
Market Cap	2.99B
Revenue (ttm)	464M
Net Income (ttm)	28.5M
	1.53
	0.22
	108.09
	18.25
P/B (ttm)	13.54
P/S (ttm)	6.44
Earnings Date	Oct 27, 2026

Ask	31.71
Volume	2,188,447
Avg. Volume (20D)	1,667,853
Open	24.96
Previous Close	25.14
Day's Range	24.60 - 25.11
52-Week Range	15.10 - 31.77
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About ARQT

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 31, 2020

Employees 354

Stock Exchange NasdaqGS

Ticker Symbol ARQT

Website https://www.arcutis.com

Full Company Profile

Financial Performance

In 2025, Arcutis Biotherapeutics's revenue was 376.07M, an increase of 91.34% compared to the previous year's 196.54M. Earnings were -16.14M, a decrease of -88.47%.

Financial Statements

Earnings Surprise

Arcutis Biotherapeutics has released their quarterly earnings on Aug 5, 2026:

Revenue of $129.86M misses estimates by $0, with 59.33% YoY growth.
EPS of 0.11 exceeds estimates by 0.06, with 184.62% YoY growth.

Next Earnings Release

Arcutis Biotherapeutics, Inc. is scheduled to release its earnings on Oct 27, 2026, after market closes.
Analysts project revenue of ... Upgrade

Why Price Moved

News

4 days ago · Simply Wall St.

Arcutis Biotherapeutics (ARQT) Faces A Valuation Test, Is It Still A Bargain?

Arcutis Biotherapeutics Stock Performance Snapshot Arcutis Biotherapeutics (ARQT) has drawn investor attention after recent share price moves, with the stock down about 12% over the past month but up ...

4 days ago · Zacks

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.

5 days ago · Zacks

5 Biotech Stocks Worth Adding to Your Portfolio Now

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli...

2 weeks ago · Motley Fool

Arcutis (ARQT) Q2 2026 Earnings Call Transcript

ZORYVE franchise revenue surged 59% year-over-year, driving profitability.

3 weeks ago · Motley Fool

Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability

Watanabe's sale was non-discretionary, executed to cover tax withholding on vesting RSUs. Watanabe retains 950,000+ shares valued at $24.65 million, signaling continued confidence.

Page 1 of 2

Arcutis Biotherapeutics, Inc. (ARQT)